Determination of the Minimum Local Analgesic Dose of Spinal Chloroprocaine in Labour
Information source: University Hospital, Ghent
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Pain Relief During Labour
Intervention: Spinal administration of chloroprocaine. (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: University Hospital, Ghent Official(s) and/or principal investigator(s): Marc Coppens, MD, Principal Investigator, Affiliation: Ghent University Hospital
Overall contact: Marc Coppens, MD, Email: Marc.Coppens@ugent.be
Summary
Combined spinal-epidural (CSE) analgesia has become a widely accepted approach to provide
analgesia for labour pain. Despite the increasingly widespread use of this technique, an
optimal intrathecal drug regimen has not been established yet.
Several investigations using local anesthetics such as Bupivacaine, Levobupivacaine and
Ropivacaine in CSE during labour have been published. But despite the reintroduction of
Chloroprocaine recently there haven't been any investigations about spinal chloroprocaine.
Chloroprocaine is already a long-know drug with a beneficial pharmacodynamic/kinetic
profile. It is known for a very quick onset of action (2 - 3 minutes), high efficacy, rapid
metabolism by plasma cholinesterases and short half-life both in mother and fetus.
Because of this beneficial profile, Chloroprocaine is widely used intrathecally for surgical
anesthesia. Several investigations demonstrate that for surgical anesthesia doses
Chloroprocaine ranging from 30 - 60 mg are used and that they have an effective surgical
duration of 40 - 90 minutes.
Despite these "standards" for surgical anesthesia, little is known about spinal
Chloroprocaine dose regimens. Therefore the primary goal of this study is to determine the
minimum adequate dose of Chloroprocaine that is to be given spinally to a woman in labour
using a CSE procedure. We will use the up-down sequential allocation to identify the median
effective dose (ED50) or concentration (EC50).
The Effective dose in 95% of the population (ED95) can be estimated also from an up-down
sequential allocation and will become an important valuable approximation of the clinical
dose.
Clinical Details
Official title: Determination of the Minimum Local Analgesic Dose of Spinal Chloroprocaine in Labour.
Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Intensity of sensory blockade during the next 15 minutes after the application of the CSE.Intensity of the motor blockade during the next 15 minutes after the application of the CSE. The analgesic effect on the labor pain during the next 15 minutes after the application of the CSE.
Secondary outcome: Maternal heart rate during application of the CSE and the hour there after.Maternal blood pressure during application of the CSE and the hour there after. Maternal oxygen saturation during application of the CSE and the hour there after. Fetal heart rate during application of the CSE and the hour there after.
Eligibility
Minimum age: 20 Years.
Maximum age: 45 Years.
Gender(s): Female.
Criteria:
Inclusion criteria :
- Pregnant women in labour with a gestational period of 36 to 41 weeks
- ASA I or II
- Primi- and multiparae
- Spontaneous or induced labor
Exclusion criteria :
Pregnant women in labour who received opiates or analgetics during the 6 hour period prior
to CSE
Locations and Contacts
Marc Coppens, MD, Email: Marc.Coppens@ugent.be
Ghent University Hospital, Ghent 9000, Belgium; Recruiting Marc Coppens, MD, Email: Marc.Coppens@ugent.be Marc Coppens, MD, Principal Investigator
Additional Information
Starting date: June 2013
Last updated: December 4, 2014
|